I thought the 3rd paper at ASCO for relatliamb (uveal melanoma: UM) might be of particular interest since UM is not particularly responsive to PD-1 therapy (i.e. in contrast to cutaneous melanoma). So, perhaps, LAG-3 therapy might provide an avenue to not only improve outcomes for patients with cancers that are responsive to PD-1 therapy, but importantly, to those patients with cancers that are less responsive (or non-responsive) to PD-1 therapy. To unlock more of the puzzle, I guess.
https://www.nature.com/articles/s41467-019-14256-1.pdf
https://en.wikipedia.org/wiki/Uveal_melanoma
From:
https://www.cancervic.org.au/cancer-information/treatments/treatments-types/immunotherapy
I thought the 3rd paper at ASCO for relatliamb (uveal melanoma:...
-
- There are more pages in this discussion • 235 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
39.0¢ |
Change
-0.010(2.50%) |
Mkt cap ! $566.5M | |||
| Open | High | Low | Value | Volume |
| 39.0¢ | 39.5¢ | 38.5¢ | $997.5K | 2.559M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 85852 | 38.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.0¢ | 75389 | 4 |
View Market Depth
| Last trade - 16.10pm 04/09/2024 (20 minute delay) ? |
| IMM (ASX) Chart |